All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

FDA Approves Nirogacestat for Desmoid Tumors

November 27th 2023

The FDA has approved nirogacestat (Ogsiveo) for adult patients with progressing desmoid tumors who require systemic treatment.

EMA Validates Application for Epcoritamab in Relapsed/Refractory Follicular Lymphoma

November 27th 2023

The European Medicines Agency has validated a type II application for the investigational T-cell engaging bispecific antibody epcoritamab-bysp for patients with relapsed/refractory follicular lymphoma following at least 2 prior lines of therapy

PC14586 Targets Previously “Undruggable” p53 in Treatment of Solid Tumors

November 27th 2023

Despite previous unsuccessful attempts to target p53, investigators have continued to try to develop novel therapeutics directed at the tumor suppressor gene with the goal of restoring p53 wild-type activity.

Dana-Farber Research Fellow Tyler Miller, MD, PhD, Receives £600,000 Grant From the Brain Tumour Charity

November 27th 2023

The Brain Tumour Charity awarded a Junior Fellows grants of £600,000 over four years - the first of its kind - to Dana-Farber Research Fellow Tyler Miller, MD, PhD.

FDA Approval Sought for Obe-Cel in Relapsed/Refractory B-ALL

November 27th 2023

A biologics license application seeking the approval of obecabtagene autoleucel for the treatment of adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia has been submitted to the FDA.

Belantamab Mafodotin Plus Bortezomib/Dexamethasone Improves PFS in R/R Multiple Myeloma

November 27th 2023

Belantamab mafodotin plus bortezomib and dexamethasone significantly improved progression-free survival compared with daratumumab plus B-Vd in the second-line treatment of patients with relapsed or refractory multiple myeloma, meeting the primary end point of the phase 3 DREAMM-7 trial.

Increasingly Specialized Clinical Trials Accelerate Advances in NSCLC Management

November 27th 2023

Subgroup analyses from non–small cell lung cancer clinical trials, such as the phase 3 POSEIDON and FLAURA2 trials, can help personalize treatment decisions with immunotherapy and targeted therapy based on individual mutational profiles.

Ongoing Research Aims to Better Define Role of ASCT in Myeloma

November 27th 2023

Marc J. Braunstein, MD, PhD, discusses the current role of autologous stem cell transplant for patients with multiple myeloma, highlighted the key factors used to determine patient eligibility, and detailed ongoing research centered around autologous stem cell transplant.

Fox Chase Cancer Center’s Edna Cukierman Awarded American Cancer Society’s Wilmott Family Professorship in Pancreatic Cancer

November 26th 2023

Edna “Eti” Cukierman, PhD, Co-Director of the Marvin & Concetta Greenberg Pancreatic Cancer Institute and Co-Leader of the Cancer Signaling and Microenvironment Research Program at Fox Chase Cancer Center, was recently awarded the American Cancer Society’s Wilmott Family Professorship in Pancreatic Cancer.

Frontline Aumolertinib Plus Anlotinib Elicits Responses in EGFR-Mutant NSCLC With Brain Metastases

November 26th 2023

Aumolertinib plus anlotinib resulted in intracranial efficacy when used in the first-line treatment of patients with EGFR-mutant non–small cell lung cancer who have brain metastases.

The US Oncology Network Extends Its Reach into Tennessee with The Addition of Nashville Oncology Associates

November 25th 2023

The Network continues its strong growth trajectory and its mission to enhance community-based cancer care.

AON Joins Nasdaq to Further Patient-Centric Community Oncology Care

November 25th 2023

The American Oncology Network has started trading on Nasdaq with the goal of continuing the growth of the organization.

Fox Chase Cancer Center’s Dr. Elizabeth Plimack Named a Fellow of the American Society of Clinical Oncology

November 24th 2023

Elizabeth Plimack, MD, MS, Deputy Director and Professor in the Department of Hematology/Oncology at Fox Chase Cancer Center, was recently recognized as a new fellow of the American Society of Clinical Oncology.

Rutgers Research Summit Aims to Broaden Oncologic Perspectives Across New Jersey

November 24th 2023

Andrew Evens, DO, MBA, MSc, highlights key points presented during the 2023 Rutgers Cancer Institute of New Jersey’s Annual Oncology Clinical Practice and Research Summit, the clinical implications of these presentations, and lymphoma treatment innovations that Rutgers Cancer Institute is providing to patients throughout New Jersey.

BASECAMP-1 Trial Aims to Identify Patients With Solid Tumors Who Are Eligible for A2B530

November 24th 2023

The observational BASECAMP-1 screening study has started to identify patients with advanced solid tumors harboring somatic human leukocyte antigen-A*02 loss of heterozygosity who would be eligible to receive the novel Tmod CAR T-cell therapy, A2B530, if their cancer relapses after standard of care treatment.

Promising New Treatment Minimizes Negative Side Effects of Chemotherapy for Small Cell Lung Cancer Patients

November 23rd 2023

Research conducted by Florida Cancer Specialists & Research Institute, LLC recently confirmed the effectiveness of a new medication in protecting bone marrow of patients who receive chemotherapy for extensive-stage small cell lung cancer.

Novel Immunomodulatory Vaccine Plus Pembrolizumab Shows Early Activity in PD-L1–High NSCLC Adenocarcinoma

November 23rd 2023

Jonathan W. Riess, MD, MS, discusses how prior data led to the investigation of IO102-IO103 in combination with pembrolizumab in patients with PD-L1–high non–small cell lung cancer adenocarcinoma and details the initial efficacy and safety data reported in this population.

Selinexor Maintenance Leads to PFS Benefit in TP53 Wild-Type Advanced/Recurrent Endometrial Cancer

November 22nd 2023

Maintenance therapy with selinexor improved progression-free survival compared with placebo in patients with TP53 wild-type advanced or recurrent endometrial cancer, regardless of microsatellite instability status.

Fruquintinib Approval Highlights Strides Made in mCRC Armamentarium in 2023

November 22nd 2023

Cathy Eng, MD, FACP, FASCO, discusses the implications of the fruquintinib approval, as well as other key clinical trial data and regulatory decisions within the colorectal cancer realm in 2023; the importance of early molecular testing in this patient population; and the continued importance of enrolling eligible patients onto clinical trials.

Toripalimab Approval Pioneers Immunotherapy Use in Nasopharyngeal Cancer

November 22nd 2023

Nabil F. Saba, MD, FACP, and Shravan Kandula, MD, highlight the significance of the approval of toripalimab for nasopharyngeal carcinoma; key data from JUPITER-02 and POLARIS-02 trials; and how the addition of this agent to the treatment armamentarium heightens the importance of multidisciplinary collaboration.